This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Take: Examining the potential of Immunogen's ELAHERE (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer.

Ticker(s): IMGN

Who's the expert?

Institution: Kaiser Permanente

  • Gynecologic Oncologist at Kaiser Permanente
  • Previously as the Director of the Division of Gynecology at Olive View-UCLA Medical Center prior to joining the Kaiser Permanente family.
  • Currently has 6 patients on Elahere

Interview Goal
Examining the potential of Immunogen's ELAHERE (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.